Five‐year efficacy and safety of tenofovir‐based salvage therapy for patients with chronic hepatitis B who previously failed <scp>LAM</scp>/<scp>ADV</scp> therapy
Lucy Lim(The University of Melbourne), Peter Angus(Atomic Weapons Establishment), Scott J. Patterson(Austin Health), William Sievert(Monash Health), Simone I. Strasser(University of Padua), Stephen Locarnini(La Trobe University), Jacob George(University of Dundee), Alice A. Lee(Palo Alto University), Scott Bowden(Victorian Infectious Diseases Reference Laboratory), Paul Desmond(The University of Melbourne), Alexander Thompson(The University of Melbourne), Stuart K. Roberts(The Alfred Hospital), Kaye Marion(Australian Mathematical Sciences Institute), Amanda Nicoll(The Royal Melbourne Hospital)
Cited by 14
Related Papers
Crystal Structures of a Complexed and Peptide-Free Membrane Protein–Binding Domain: Molecular Basis of Peptide Recognition by PDZ
|Cell|1996|1.1k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
|Hepatology International|2008|870
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
|Gastroenterology|2009|693
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
|New England Journal of Medicine|2017|565